Carrie Bourdow
Chief Executive Officer bei TREVENA, INC.
Vermögen: 43 442 $ am 31.03.2024
Aktive Positionen von Carrie Bourdow
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| TREVENA, INC. | Chief Executive Officer | 01.10.2018 | - |
| Chairman | 01.01.2024 | - | |
| President | 01.10.2018 | - | |
| Director/Board Member | 01.10.2018 | 01.01.2024 | |
| Chief Operating Officer | 02.02.2018 | 01.10.2018 | |
| Corporate Officer/Principal | 04.05.2015 | 02.02.2018 |
Karriereverlauf von Carrie Bourdow
Ehemalige bekannte Positionen von Carrie Bourdow
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| NABRIVA THERAPEUTICS PLC | Director/Board Member | 23.06.2017 | 30.07.2023 |
| Independent Dir/Board Member | 23.06.2017 | 30.07.2023 | |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 20.02.2020 | 07.03.2023 |
| Independent Dir/Board Member | 20.02.2020 | 07.03.2023 | |
| CUBIST PHARMACEUTICALS INC | Sales & Marketing | 01.05.2013 | 01.05.2015 |
Ausbildung von Carrie Bourdow
| Hendrix College | Undergraduate Degree |
| Southern Illinois University | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 6 |
| Irland | 2 |
Operativ
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| TREVENA, INC. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Carrie Bourdow
- Erfahrung
